Legal & General Group PLC Revance Therapeutics, Inc. Transaction History
Legal & General Group PLC
- $470 Billion
- Q3 2024
A detailed history of Legal & General Group PLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 111,628 shares of RVNC stock, worth $286,883. This represents 0.0% of its overall portfolio holdings.
Number of Shares
111,628
Previous 111,628
-0.0%
Holding current value
$286,883
Previous $286,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding RVNC
# of Institutions
234Shares Held
82.8MCall Options Held
680KPut Options Held
896K-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.73MShares$14.7 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.78MShares$12.3 Million0.0% of portfolio
-
Fil LTD Hamilton, D04.19MShares$10.8 Million0.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ4.16MShares$10.7 Million0.49% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...